ABSTRACT
Background: To assess the effect of oral iron supplementation on quality of life (QOL) in anemic patients with heart failure (HF) and to compare QOL with HF patients without iron treatment. Methods: Sixty anemic patients (Hb 8-11g/dl) with HF (NYHA-class II and III) with LVEF<40% were divided in to 2 groups of 30 each. Group I- received ferrous sulfate 100mg bid x 90 days + standard treatment for HF. Group II- anemic patients received standard treatment for HF only. Primary end point- QOL was measured by MLWHF questionnaire. Secondary end points are Borg scale for dyspnoea and fatigue and exercise tolerance/ capacity in the form of 6 min. walk distance, haematological parameters, efficacy and safety assessment. Results: There was significant improvement in QOL in iron treated patients as compared to group II (control). Exercise tolerance /capacity, Borg scale for fatigue and dyspnoea showed improvement in patients received iron for 90 days. Haematological parameters were improved gradually with less incidence of fatigue and pallor. Orally administered ferrous sulfate was well tolerated with mild side effects. Conclusions: Oral iron supplementation in anemic patients with heart failure improves quality of life/ physical functioning in these patients.
ABSTRACT
Objectives : To compare the gingival crevicular fluid (GCF) myeloperoxidase (GM) levels in smokers and non-smokers. Materials and methods : This study comprised 45 subjects: (a) 12 smokers with periodontitis, (b) 10 non-smokers with periodontitis, (c) 11 smokers with healthy periodontium, and (d) 12 non-smokers with healthy periodontium were recruited for the study and their GM levels were analyzed. Results and conclusion : GM levels were significantly higher in smokers with periodontitis compared with others. Hence, more incidence of mutagenesis and cytotoxicity were noted at sites of inflammation mediated by GM in smokers compared with non-smokers.